Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-04-28 AGM Information
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
关于召开2021年年度股东大会通知公告提供网络投票
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2021 Annual General Meeting (AGM) of Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items to be discussed, and procedural information for shareholders. It does not contain the actual annual report or financial statements but references other announcements where reports can be found. The document is under 5,000 characters and serves as a meeting notice rather than the report itself. Therefore, it fits the category of AGM Information (AGM-R).
2022-04-28 Chinese
监事会对关于2021年财务审计报告非标准审计意见专项说明的议案的意见
Audit Report / Information Classification · 95% confidence The document is a statement from the Supervisory Board regarding the auditor's issuance of a non-standard (qualified) audit opinion on the company's 2021 financial statements. It includes the Supervisory Board's opinion on the audit report and mentions the auditor's reserved opinion. The document is short (541 characters) and does not contain the full audit report or detailed financial data, but rather a commentary on the audit opinion. This fits the category of an Audit Report / Information (AR) as it relates to audit opinions and explanations, not a full Annual Report or a simple announcement. Therefore, the classification is AR with high confidence. FY 2021
2022-04-28 Chinese
第四届监事会第二次决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of various proposals including the 2021 Supervisory Board Work Report, 2022 Business Plan, 2021 Financial Statements, 2022 Financial Budget, Profit Distribution, Reappointment of Accounting Firm, Annual Report and Summary, Related Party Transactions, Quarterly Report, Audit Report Explanation, and Self-Inspection Report on Non-operating Fund Occupation by Controlling Shareholders. The document is a formal announcement of the resolutions passed at the Supervisory Board meeting, not the reports themselves. It references other announcements where the full reports are published. The document length is 3291 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of meeting resolutions and references other filings for detailed reports.
2022-04-28 Chinese
续聘会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (信永中和会计师事务所) for auditing services for the year 2022. It details the accounting firm's background, integrity records, audit fees, and the board's approval process. There is no actual audit report or financial statements included, only information about the appointment process and related approvals. The document length is 2747 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates to audit firm appointment and audit-related information but is not the full audit report itself. FY 2022
2022-04-28 Chinese
2021年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告 2021' which translates to 'Annual Report 2021'. It contains detailed sections typical of an annual report such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management information, industry information, corporate governance, internal control, and financial accounting reports. The document includes comprehensive financial data, business performance analysis, risk disclosures, and detailed operational and financial metrics for the year 2021. It also references the audit report with a qualified opinion from the accounting firm, which is typical in annual reports. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-28 Chinese
董事会关于控股股东关联方非经营性资金占用自查报告及整改方案
Board/Management Information Classification · 95% confidence The document is a public announcement by the board of directors of Yunnan Biological Valley Pharmaceutical Co., Ltd. regarding a self-inspection report and rectification plan related to non-operating funds occupied by the controlling shareholder and its related parties. It details the situation of fund occupation, repayment status, and internal corrective measures. The content focuses on governance issues, internal control, and shareholder fund management rather than financial results or audit opinions. It is not an annual report, audit report, earnings release, or any financial statement. It is also not a regulatory filing or certification letter. The document is a detailed report from the board addressing a specific governance and financial control issue, which fits best under Board/Management Information (MANG). The document length is 2056 characters, which is relatively short but contains substantive content about board-level decisions and management actions.
2022-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.